

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

[LAU-Me275](#)

RRID:CVCL_S597

Type: Cell Line

Proper Citation

RRID:CVCL_S597

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_S597

Proper Citation: RRID:CVCL_S597

Description: Cell line LAU-Me275 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cutaneous melanoma

Defining Citation: [PMID:9469433](#), [PMID:20862285](#), [PMID:21494657](#), [PMID:22197931](#)

Comments: From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LAU-Me275

Synonyms: LAUMe275, Me275, Me 275, LAU50_1

Cross References: cancercellines:CVCL_S597, Cosmic:1675356, GEO:GSM566196, GEO:GSM566255, GEO:GSM566256, GEO:GSM566257, GEO:GSM566258, GEO:GSM568793, Progenetix:CVCL_DI19, Progenetix:CVCL_S597, Wikidata:Q54901949

ID: CVCL_S597

Record Creation Time: 20220427T220717+0000

Record Last Update: 20260905T181008+0000

Ratings and Alerts

No rating or validation information has been found for LAU-Me275.

No alerts have been found for LAU-Me275.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang S, et al. (2026) A CD8?? co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands. Nature communications, 17(1), 753.

Chiri?oiu GN, et al. (2023) Methionine oxidation selectively enhances T cell reactivity against a melanoma antigen. iScience, 26(7), 107205.

Yu CI, et al. (2021) Human KIT+ myeloid cells facilitate visceral metastasis by melanoma. The Journal of experimental medicine, 218(6).

Murata K, et al. (2020) Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. eLife, 9.